Table 1 Progression-free survival Cox regression analysis c-scores for 210 patients with non-squamous carcinoma.

From: Development of a prognostic multiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first line immunotherapy

Model

Components

Fivefold cross-validated c-score, 95% CI

Clinical model

BMI, smoking status

0.58, [0.52, 0.61]

Combination model

Radiomic phenotypes, radiological variables (SUVmax, longest tumor diameter at baseline), pathological variable (PD-L1 expression)

0.63, [0.53, 0.64]

Combination clinical model

Radiomic phenotypes, radiological variables (SUVmax, longest tumor diameter at baseline), pathological variable (PD-L1 expression), BMI, smoking status

0.68, [0.58,0.69]

Multiomic graph phenotypes

Multiomic graph phenotypes

0.65, [0.56, 0.67]

Multiomic graph clinical model

Multiomic graph phenotypes, BMI, smoking status

0.71, [0.61, 0.72]